GlassScriptPhysician profile
Kevin Charles Frame
NPI 1235278268
$3,469.94
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,253 · 2020: $92.48 · 2021: $32.54 · 2022: $91.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,159.62 | 2019 | |
| Canon Medical Systems USA, INC. | $628.97 | 2019 | |
| Cardiovascular Systems INC. | $248.32 | 2019-2020 | |
| Becton, Dickinson and Company | $118.03 | 2020-2022 | |
| Bard Peripheral Vascular, INC. | $117.00 | 2019 | |
| Angiodynamics, INC. | $45.90 | 2020 | |
| Medtronic USA, INC. | $43.98 | 2019 | |
| Boston Scientific Corporation | $39.56 | 2019 | |
| Ge Healthcare | $26.65 | 2019 | |
| Siemens Medical Solutions USA, INC. | $22.03 | 2022 | |
| Covidien LP | $19.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Frame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.